As a result, 12 genes were found to be downregulated following gilteritinib therapy, including CENPE, MCM4, GSPT1, MMS22L, DDX21, VDAC1, FDX1, OPA1, PDHX, ELOA, BCL3, and RACGP1, in EC, OC and GC TCGA cohort (Supplemental Fig. 4). This evidence concerns the gene MCM4 and gastric cancer.